Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$56.72 USD

56.72
1,625,021

+0.53 (0.94%)

Updated Oct 3, 2025 04:00 PM ET

After-Market: $56.60 -0.12 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Exact Sciences (EXAS) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Exact Sciences (EXAS) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Zacks Equity Research

DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute

by Zacks Equity Research

Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.

Zacks Equity Research

Why Exact Sciences (EXAS) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Why Is Kodiak Sciences (KOD) Down 1.2% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs

by Zacks Equity Research

EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.

Zacks Equity Research

Should You Continue to Hold EXAS Stock in Your Portfolio?

by Zacks Equity Research

Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.

Zacks Equity Research

What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?

by Zacks Equity Research

TEM's Q2 net loss narrows sharply, driven by surging genomics revenues, higher gross profits and tighter cost controls.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

TMO Receives FDA Approval for Oncomine Dx Target Test

by Zacks Equity Research

Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.

Sridatri Sarkar headshot

TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?

by Sridatri Sarkar

Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.

Zacks Equity Research

EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up

by Zacks Equity Research

Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.

Zacks Equity Research

Here's Why Exact Sciences (EXAS) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates

by Zacks Equity Research

Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.

Zacks Equity Research

PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues

by Zacks Equity Research

Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.

Zacks Equity Research

Exact Sciences (EXAS) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Exact Sciences (EXAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

by Zacks Equity Research

Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.

Zacks Equity Research

Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of +1,200.00% and +4.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +9.68% and -0.85%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?

by Zacks Equity Research

VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.

Zacks Equity Research

Zimmer Biomet to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

ZBH's Q2 results may show strength in Hips, Knees, and S.E.T. despite a projected year-over-year earnings dip.

Zacks Equity Research

TG Therapeutics (TGTX) Misses Q2 Earnings Estimates

by Zacks Equity Research

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and +3.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.

Zacks Equity Research

Will Healthcare Growth Help STE Beat on Q1 Earnings?

by Zacks Equity Research

STERIS is likely to have experienced a strong Q1 with 14.3% EPS growth as Healthcare and AST segments show solid momentum.